News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
370,680 Results
Type
Article (25571)
Company Profile (64)
Press Release (345045)
Section
Business (104039)
Career Advice (439)
Deals (16857)
Drug Delivery (40)
Drug Development (47382)
Employer Resources (47)
FDA (12170)
Job Trends (8409)
News (185253)
Policy (19367)
Tag
Academia (1729)
Africa (351)
Allergies (35)
Alliances (26478)
Alzheimer's disease (677)
Approvals (12129)
Arizona (79)
Artificial intelligence (41)
Asia (23820)
Australia (3756)
Bankruptcy (134)
Best Places to Work (6670)
Biotechnology (42)
Breast cancer (43)
C2C Services and Suppliers (57501)
California (977)
Canada (564)
Cancer (329)
Career advice (398)
Cell therapy (62)
China (97)
Clinical research (38660)
Collaboration (72)
Colorado (47)
Connecticut (46)
COVID-19 (1414)
Data (234)
Diabetes (53)
Diagnostics (3254)
Drug pricing (40)
Earnings (35421)
Employer resources (43)
Europe (46327)
Events (49580)
Executive appointments (102)
FDA (12350)
Florida (176)
Funding (78)
Gene therapy (33)
Georgia (35)
GLP-1 (278)
Government (2975)
Healthcare (12095)
Hotbed/Location (248667)
Idaho (33)
Illinois (165)
Indiana (100)
Infectious disease (1430)
Inflammatory bowel disease (63)
Interviews (37)
IPO (6942)
Job creations (1833)
Job search strategy (373)
Kansas (67)
Layoffs (147)
Legal (3602)
Liver cancer (44)
Lung cancer (84)
Manufacturing (32)
Maryland (309)
Massachusetts (697)
Medical device (12574)
Medtech (12577)
Mergers & acquisitions (9905)
Metabolic disorders (155)
Michigan (52)
Minnesota (139)
Neuroscience (758)
New Hampshire (47)
New Jersey (349)
New York (322)
NextGen Class of 2024 (3919)
Non-profit (2807)
North Carolina (335)
Northern California (451)
Obesity (97)
Ohio (63)
Opinion (59)
Patents (39)
Pennsylvania (354)
People (33829)
Phase I (11007)
Phase II (16758)
Phase III (13771)
Pipeline (66)
Postmarket research (1662)
Preclinical (3450)
Rare diseases (60)
Real estate (2834)
Regulatory (13433)
Research institute (1594)
Resumes & cover letters (48)
South America (512)
Southern California (418)
Startups (2114)
Texas (152)
United States (4781)
Vaccines (242)
Washington State (86)
Weight loss (85)
Date
Today (60)
Last 7 days (414)
Last 30 days (1446)
Last 365 days (21010)
2024 (14708)
2023 (22736)
2022 (30680)
2021 (32985)
2020 (32195)
2019 (28414)
2018 (21811)
2017 (18908)
2016 (18111)
2015 (21194)
2014 (16023)
2013 (13241)
2012 (14349)
2011 (14622)
2010 (13181)
370,680 Results for "actinogen medical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Enrollment completed in Actinogen’s XanaCIDD phase 2a cognition & depression trial
Actinogen Medical Limited (ASX: ACW) announces the full enrollment of 167 participants in the Company’s XanaCIDD phase 2a clinical trial in patients with cognitive impairment in major depressive disorder (MDD).
April 22, 2024
·
7 min read
Drug Development
First patient treated in Actinogen’s XanaMIA phase 2b Alzheimer’s disease trial
Actinogen Medical Limited announces that the first patient has been randomized and treated in the XanaMIA phase 2b clinical trial in patients with biomarker-positive mild to moderate Alzheimer’s disease (AD).
April 15, 2024
·
8 min read
Press Releases
Actinogen announces further positive results on depression in the XanCIDD phase 2a trial
August 26, 2024
·
9 min read
Press Releases
Actinogen announces achievement of clinically and statistically significant superiority of Xanamem® over placebo on depression in XanaCIDD phase 2a trial
August 12, 2024
·
10 min read
Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer’s Disease (CTAD) Conference, Boston
Actinogen Medical Limited (ASX: ACW) CEO Dr Steven Gourlay will conduct a series of meetings at the BIO Investor Forum, San Francisco on October 17-18, 2023.
October 13, 2023
·
8 min read
Drug Development
Actinogen optimizes XanaMIA Phase 2b Alzheimer’s disease trial design and provides general business update
Actinogen Medical Limited (ASX: ACW) is pleased to announce optimization of the XanaMIA Phase 2b trial in patients with mild-to-moderate Alzheimer’s disease to reduce the cost and time to initial results.
September 26, 2023
·
9 min read
Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer’s Disease Phase 2 trials at the BIO International Convention
Actinogen Medical Limited (ASX: ACW) CEO Dr Steven Gourlay and CMO Dr Dana Hilt will present at the BIO International Convention, to be held at the Boston Convention & Exhibition Center from June 5-8, 2023.
May 31, 2023
·
7 min read
Drug Development
Positive Xanamem® biomarker trial published in the Journal of Alzheimer’s Disease demonstrating potential Xanamem efficacy in patients with elevated blood pTau
Actinogen Medical Limited announces the peer-reviewed publication of its phase 2a biomarker trial entitled “Plasma pTau181 Predicts Clinical Progression In A Phase 2 Randomized Controlled Trial of the 11β-HSD1 Inhibitor Xanamem for Mild Alzheimer’s Disease” in the 100th edition of the Journal of Alzheimer’s Disease.
June 26, 2024
·
9 min read
Actinogen presents positive Phase 2a Xanamem data in at ADPD™ Alzheimer’s and Parkinson’s diseases conference
Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that its Chief Medical Officer, Dr Dana Hilt will make an oral presentation to the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (ADPD™ 2023) later today in Gothenburg, Sweden.
March 30, 2023
·
6 min read
Drug Development
Actinogen Medical Limited (ACW) announces large Xanamem® therapeutic effect in early-stage Alzheimer’s Disease (AD) patients
Actinogen Medical Limited (ASX: ACW) today announces positive Phase 2a clinical data from its Alzheimer’s Disease (AD) biomarker study.
October 10, 2022
·
10 min read
1 of 37,068
Next
